title: Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors.
authors.affiliation: The Preston Robert Tisch Brain Tumor Center at Duke, Durham, NC, USA. rebecca.liu@duke.edu
authors.forename: Rebecca
authors.initials: R
authors.lastname: Liu
authors.forename: Duane A
authors.initials: DA
authors.lastname: Mitchell
mesh_terms: D000328:Adult; D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D017209:Apoptosis / Q000235:genetics / Q000276:immunology; D001932:Brain Neoplasms / Q000628:therapy*; D019496:Cancer Vaccines / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051034:Inhibitor of Apoptosis Proteins; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000276:immunology / Q000628:therapy; D000077022:Survivin
chemical_list: D000951:Antigens, Neoplasm; C107489:BIRC5 protein, human; D019496:Cancer Vaccines; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D000077022:Survivin